文献速递胸部肿瘤

晚期恶性胸膜间皮瘤肿瘤免疫微环境的分子与组织病理学特征

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2017-10-24

该研究对99例晚期恶性胸膜间皮瘤(MPM)存档肿瘤进行PD-L1免疫组化检测,其中87例经NanoString分析800个免疫相关基因表达。PD-L1在16%的肿瘤样本中表达,基因表达分析提示MPM为炎症型肿瘤,可分为三个免疫相关基因表达谱不同的亚组,其中两组显示不同程度的免疫相关基因表达。PD-L1阳性或炎症状态的MPM亚组占60%,可能对免疫治疗有反应。

要点

  • 晚期MPM中PD-L1表达率为16%,见于肿瘤细胞或浸润免疫细胞。
  • 基于免疫相关基因表达谱,MPM可分为三个不同亚组。
  • PD-L1阳性或炎症状态的亚组合计占MPM的60%,可能是免疫治疗候选亚型。

核心结论

  • PD-L1表达或炎症状态的MPM患者占60%,是癌症免疫治疗的潜在候选人群。

研究设计与样本

  • 对99例晚期MPM存档肿瘤在两个实验室平行进行PD-L1免疫组化检测。
  • 其中87例通过NanoString分析对800个基因进行免疫基因表达谱分析。

主要发现

  • PD-L1表达见于16%的MPM肿瘤样本,表达于肿瘤细胞或浸润免疫细胞。
  • 基因表达分析提示MPM为炎症型肿瘤,基于免疫相关基因表达谱可分为三个亚组。
  • 三个亚组中有两组显示不同程度的免疫相关基因表达。
  • PD-L1阳性及免疫相关基因表达的亚组合计占MPM的60%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, and relatively chemoresistant and radioresistant malignancy with limited therapeutic options. Our objective was to investigate the prevalence of programmed death ligand 1 (PD-L1) and the characteristics of the immune environment in this disease. METHODS: A total of 99 archival tumors from advanced-stage MPM were immunohistochemically tested in parallel for PD-L1 in two different laboratories, and 87 of them were profiled for immune gene expression by NanoString analysis for 800 genes. A prior study on the same samples indicated a low mutational load with a complex mutational landscape of genetic variations more frequently associated with the p53/DNA repair and phosphoinisitide-3-kinase pathways. RESULTS: PD-L1 expression was found in 16% of the MPM tumor samples, either in the tumor cells or the infiltrating immune cells. Gene expression analysis suggested that MPM is an inflamed tumor type and can be classified into three different subgroups on the basis of the different expression profiles of immune-related genes, of which two groups showed varying degrees of expression of immune-related genes. Overall, these molecular findings suggest that these subgroups of MPM associated with PD-L1 positivity and expression of immune-related genes accounting for 60% of MPMs represent a candidate subtype that may respond to cancer immunotherapy. CONCLUSIONS: These data suggest that 60% of patients with MPM characterized by either PD-L1 expression or an inflamed status are attractive candidates for cancer immunotherapeutic options.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Patil NS, Righi L, Koeppen H, et al. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. J Thorac Oncol. 2017. PMID: 29079455. doi:10.1016/j.jtho.2017.09.1968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。